Kobrin 1991.

Methods	4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 100‐115 mm Hg at last 2 visits of run‐in; 4‐week double‐blind treatment
Participants	Cilazapril 2.5 mg: n=29(18 males,11 females); mean age=50(9) years; Cilazapril 5 mg: n=29(16 males,13 females); mean age=48(9) years; Placebo: n=28(13 males,15 females); mean age=52(8) years
Interventions	Cilazapril 2.5 mg once daily; Cilazapril 5 mg once daily; Placebo
Outcomes	Mean change from baseline in trough sitting DBP using mercury sphygmomanometer; WDAE
Notes	SBP change not reported; DBP change and SE of change reported, endpoint BP and SD not reported; calculated DBP SD of change from N and SE of change; BP data from Table II, p. 34; Jadad score=3; funding source= Hoffman‐La Roche Ltd. Kobrin 1991 reports results for 2 independent RCTs. Study 2 is same RCT as reported in Guntzel 1991. Data for Study 1 is entered as Kobrin 1991.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear